Series 2 - Nitrosamine Sources
2# What causes nitrosamines presence?
Technically, nitrosamines may be present due to contamination
or intrinsic formation by the reaction of two existing essential components
during the manufacturing process: 1) amines and 2) nitrites, under certain
conditions (heat, pH, and water content). All amines, including primary,
secondary, tertiary, and quaternary, can possibly form nitrosamines. However, secondary
amines are the most reactive ones, as they can react directly with nitrites and
produce stable nitrosamines (see Figure 1).
Figure 1. The Primary, Secondary, and Tertiary Amine Reaction with Nitrites |
Drug
products comprise Active Pharmaceutical Ingredients (API) and additive
substances called excipients. Amines may exist in the drug product, such as in
the API structure formula or from excipients, as well as solvents or reagents
used in manufacturing. Several common solvents used are Dimethylformamide (containing
Dimethylamine as secondary amines) and N-methyl pyrrolidinone (NMP), which, if it
undergoes a hydrolysis process, will produce the N-methyl amino-N-butyric acid (which
is a secondary amine). Later, with the contribution of nitrites and supporting
condition presence, these secondary amines may generate nitrosamine impurities
(see Figure 2). Therefore, secondary amines became the most interesting target
analytes to be identified and quantified in drug products as part of the effort
to minimise nitrosamine formation. See also Figure 3 for several common
secondary amines used as solvents.
Figure 2. Reaction of N, N-dimethylamine with Nitrite to Form NDMA |
Figure 3. Secondary Amines Contained in Pharmaceutical Solvents |
But how can we actually analyse amine compounds?
References:
- H. Akkaraju, R. Tatia, S. S. Mane, A. B. Khade and S. J. Dengale, Regulatory Toxicology and Pharmacology, 2023, 139, DOI: 10.1016/j.yrtph.2023.105355.
- S. Horne, M. D. Vera, L. R. Nagavelli, V. A. Sayeed, L. Heckman, D. Johnson, D. Berger, Y. Y. Yip, C. L. Krahn, L. O. Sizukusa, N. F. M. Rocha, R. N. Bream, J. Ludwig, D. A. Keire and G. Condran, J Pharm Sci, 2023, 112, 1166–1182.
- M. Homšak, M. Trampuž, K. Naveršnik, Z. Kitanovski, M. Žnidarič, M. Kiefer and Z. Časar, Processes, 2022, 10, DOI:10.3390/pr10112428.
- C. J. Borths, T. Burr, A. Figuccia, J. G. Ford, B. Guan, M. T. Jones, D. Klingeleers, S. Lochner, A. A. Rodriguez and C. Wetter, Org Process Res Dev, 2023, 27, 1693-1702.
Comments
Post a Comment